Exploring the Therapeutic Potential of Paenibacillus-Derived Exopolysaccharides in Colorectal Cancer: A Cellular and Inflammatory Perspective

Abstract

This study seeks to explore the possibility of discovering a novel therapeutic agent for colorectal cancer. The exopolysaccharide (EPS-J12) from Paenibacillus spp. PYQ-J12 was used as the experimental subject. Caco-2 cells were used to simulate impaired intestinal epithelial cells, and TNF-α was used to cause inflammation of the cells, which was expected to investigate the reparative functions of EPS on inflamed, damaged Caco-2 cells and its influence on the expression levels of different inflammatory factors. Cell viability was used as an indicator to evaluate the reparative effects of the polysaccharide. The expression levels of different cytokines, including Interleukin 6 (IL-6), IL-8, IL-10, IL-1β, and Interleukin 12A (IL-12A), were tested. The findings indicated that EPS has a certain repair effect on inflammatory damage and can cause a reduction in the expression levels of inflammatory factors, thereby controlling inflammation. Therefore, it has the potential to become a new therapeutic option.